Healthcare Industry News: UCB
News Release - September 19, 2006
UCB Appoints Fabrice Egros, Ph.D., MBA, President of U.S. SubsidiaryFormer President of UCB Japan Looks Toward Significant Innovation and Growth for U.S. Operations
ATLANTA, Sept. 19 (HSMN NewsFeed) -- UCB, a global research-based biopharmaceutical leader with worldwide headquarters in Brussels, Belgium, has appointed Fabrice Egros, Ph.D., MBA, President of its U.S. subsidiary.
Dr. Egros brings a distinguished twenty-year, international career in the pharmaceutical industry and comes to UCB, Inc., from his position as President of UCB Japan, where he was responsible for remarkable growth and record sales. Prior to joining UCB, Dr. Egros built his solid pharmaceutical expertise with companies such as Parke-Davis/Warner Lambert in Germany and the U.S. and sanofi-aventis in Japan and the U.S., where he assumed responsibilities in a diverse range of roles, such as clinical development, managed care, medical affairs, marketing, and general management.
"This is an exciting time for UCB, Inc., as we embark on new product introductions flowing out of our rich research and development pipeline," said Dr. Egros. "I feel that the combination of my broad, global experiences will further strengthen the presence of UCB in the U.S. UCB is truly driven by the passionate desire to liberate families living with severe diseases, so that they can enjoy everyday, normal lives."
Dr. Egros earned a doctorate degree in pharmaceutical sciences from Chatenay Malabry University, in Paris, France. He holds master's degrees in computer sciences and pharmacokinetics and drug metabolism from Orsay University, Paris, France, as well as a master's degree in business administration from Schiller International University, Dunedin, Florida. Additionally, Dr. Egros has completed the Advanced Management Program at Harvard University, Cambridge, Massachusetts.
UCB (http://www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders, and oncology -- UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in 40 countries, UCB achieved revenues of euro 2.3 billion in 2005. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters are located in Brussels, Belgium, and U.S. headquarters are located in Atlanta, Georgia.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsEuropean Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture